Pathogenic mutation of ALK2 inhibits induced pluripotent stem cell reprogramming and maintenance: Mechanisms of reprogramming and strategy for drug identification

Stem Cells

Volumn 30, Issue 11, 2012, Pages 2437-2449

  Hamasaki, Makoto ^a   Hashizume, Yoshinobu ^b   Yamada, Yoshinori ^a   Katayama, Tomohiko ^a   Hohjoh, Hirohiko ^c   Fusaki, Noemi ^d   Nakashima, Yasuharu ^e   Furuya, Hirokazu ^f   Haga, Nobuhiko ^g   Takami, Yoichiro ^a   Era, Takumi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b RIKEN   (Japan)

^c NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^d University of Tokyo   (Japan)

^e KYUSHU UNIVERSITY   (Japan)

^f Omuta National Hospital   (Japan)

^g UNIVERSITY OF TOKYO   (Japan)

Author keywords

Experimental models; Induced pluripotent stem cells; Pluripotency; Reprogramming

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 2 INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CASE REPORT; CELL LINEAGE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG SCREENING; ENDODERM; ENZYME INHIBITION; FEMALE; FIBRODYSPLASIA OSSIFICANS PROGRESSIVA; GENE MUTATION; HUMAN; HUMAN CELL; MALE; MESODERM; OSSIFYING MYOSITIS; PHENOTYPE; PLURIPOTENT STEM CELL; SKIN FIBROBLAST;

ACTIVIN RECEPTORS, TYPE I; ANIMALS; CELL DIFFERENTIATION; CELL LINEAGE; CELLS, CULTURED; COCULTURE TECHNIQUES; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATION; FIBROBLASTS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MICE; MUTATION, MISSENSE; MYOSITIS OSSIFICANS; PHENOTYPE; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIMIDINES; SIGNAL TRANSDUCTION; SKIN; TRANSCRIPTOME;

EID: 84867903696     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1221     Document Type: Article

References (49)

1. Kaplan FS, Seemann P, Haupt J et al. Investigations of activated ACVR1/ALK2, a bone morphogenetic protein type I receptor, that causes fibrodysplasia ossificans progressiva. Methods Enzymol 2010;484:357-373.
2. Shore EM, Kaplan FS. Insights from a rare genetic disorder of extraskeletal bone formation, fibrodysplasia ossificans progressiva (FOP). Bone 2008;43:427-433.
3. Fukuda T, Kohda M, Kanomata K et al. Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva. J Biol Chem 2009;284:7149-7156.
4. Billings PC, Fiori JL, Bentwood JL et al. Dysregulated BMP signaling and enhanced osteogenic differentiation of connective tissue progenitor cells from patients with fibrodysplasia ossificans progressiva (FOP). J Bone Miner Res 2008;23:305-313. (Pubitemid 351304661)
5. Fiori JL, Billings PC, de la Pena LS et al. Dysregulation of the BMP-p38 MAPK signaling pathway in cells from patients with fibrodysplasia ossificans progressiva (FOP). J Bone Miner Res 2006;21:902-909. (Pubitemid 43787997)
6. Kaplan FS, Xu M, Seemann P et al. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat 2009;30:379-390.
7. Shafritz AB, Shore EM, Gannon FH et al. Overexpression of an osteogenic morphogen in fibrodysplasia ossificans progressiva. N Engl J Med 1996;335:555-561. (Pubitemid 26272310)
8. Shen Q, Little SC, Xu M et al. The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization. J Clin Invest 2009;119:3462-3472.
9. Shore EM, Xu M, Feldman GJ et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 2006;38:525-527.
10. Furuya H, Ikezoe K, Wang L et al. A unique case of fibrodysplasia ossificans progressiva with an ACVR1 mutation, G356D, other than the common mutation (R206H). Am J Med Genet A 2008;146A:459-463. (Pubitemid 351206817)
11. Fukuda T, Kanomata K, Nojima J et al. A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type i receptor. Biochem Biophys Res Commun 2008;377:905-909.
12. Dimos JT, Rodolfa KT, Niakan KK et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008;321:1218-1221.
13. Ebert AD, Yu J, Rose FF, Jr. et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009;457:277-280.
14. Liu GH, Barkho BZ, Ruiz S et al. Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome. Nature 2011;472:221-225.
15. Marchetto MC, Carromeu C, Acab A et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 2010;143:527-539.
16. Soldner F, Hockemeyer D, Beard C et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009;136:964-977.
17. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-676. (Pubitemid 44233629)
18. Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-872. (Pubitemid 350138099)
19. Itzhaki I, Maizels L, Huber I et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011;471:225-229.
20. Koch P, Breuer P, Peitz M et al. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature 2011;480:543-546.
21. Yazawa M, Hsueh B, Jia X et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 2011;471:230-234.
22. Hong H, Takahashi K, Ichisaka T et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 2009;460:1132-1135.
23. Li H, Collado M, Villasante A et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 2009;460:1136-1139.
24. Fusaki N, Ban H, Nishiyama A et al. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B Phys Biol Sci 2009;85:348-362.
25. Seki T, Yuasa S, Oda M et al. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell 2010;7:11-14.
26. Ban H, Nishishita N, Fusaki N et al. Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc Natl Acad Sci USA 2011;108:14234-14239.
27. Yu PB, Deng DY, Lai CS et al. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med 2008;14:1363-1369.
28. Cuny GD, Yu PB, Laha JK et al. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg Med Chem Lett 2008;18:4388-4392.
29. Tada S, Era T, Furusawa C et al. Characterization of mesendoderm: A diverging point of the definitive endoderm and mesoderm in embryonic stem cell differentiation culture. Development 2005;132:4363-4374. (Pubitemid 41576697)
30. Sakurai H, Era T, Jakt LM et al. In vitro modeling of paraxial and lateral mesoderm differentiation reveals early reversibility. Stem Cells 2006;24:575-586. (Pubitemid 44464761)
31. Niwa H, Toyooka Y, Shimosato D et al. Interaction between Oct3/4 and Cdx2 determines trophectoderm differentiation. Cell 2005;123:917-929. (Pubitemid 41721036)
32. Takashima Y, Era T, Nakao K et al. Neuroepithelial cells supply an initial transient wave of MSC differentiation. Cell 2007;129:1377-1388. (Pubitemid 46970707)
33. Niwa H, Miyazaki J, Smith AG. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 2000;24:372-376. (Pubitemid 30187435)
34. Mitsui K, Tokuzawa Y, Itoh H et al. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 2003;113:631-642. (Pubitemid 36694188)
35. Chambers I, Colby D, Robertson M et al. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 2003;113:643-655. (Pubitemid 36694189)
36. Raychaudhuri S, Stuart JM, Altman RB. Principal components analysis to summarize microarray experiments: Application to sporulation time series. Pac Symp Biocomput2000:455-466.
37. Takahashi M, Katagiri T, Furuya H et al. Disease-causing allele-specific silencing against the ALK2 mutants, R206H and G356D, in fibrodysplasia ossificans progressive. Gene Ther 2012;19:781-785.
38. Ichida JK, Blanchard J, Lam K et al. A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog. Cell Stem Cell 2009;5:491-503.
39. Attisano L, Carcamo J, Ventura F et al. Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors. Cell 1993;75:671-680. (Pubitemid 23346366)
40. Maherali N, Hochedlinger K. Tgfbeta signal inhibition cooperates in the induction of iPSCs and replaces Sox2 and cMyc. Curr Biol 2009;19:1718-1723.
41. Samavarchi-Tehrani P, Golipour A, David L et al. Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. Cell Stem Cell 2010;7:64-77.
42. Balemans W, Van Hul W. Extracellular regulation of BMP signaling in vertebrates: A cocktail of modulators. Dev Biol 2002;250:231-250. (Pubitemid 35216412)
43. Watabe T, Miyazono K. Roles of TGF-beta family signaling in stem cell renewal and differentiation. Cell Res 2009;19:103-115.
44. Aoki H, Fujii M, Imamura T et al. Synergistic effects of different bone morphogenetic protein type I receptors on alkaline phosphatase induction. J Cell Sci 2001;114:1483-1489. (Pubitemid 32427835)
45. Brederlau A, Faigle R, Elmi M et al. The bone morphogenetic protein type Ib receptor is a major mediator of glial differentiation and cell survival in adult hippocampal progenitor cell culture. Mol Biol Cell 2004;15:3863-3875. (Pubitemid 38989720)
46. Ying QL, Nichols J, Chambers I et al. BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. Cell 2003;115:281-292. (Pubitemid 37487702)
47. Xu RH, Chen X, Li DS et al. BMP4 initiates human embryonic stem cell differentiation to trophoblast. Nat Biotechnol 2002;20:1261-1264. (Pubitemid 35462493)
48. West FD, Roche-Rios MI, Abraham S et al. KIT ligand and bone morphogenetic protein signaling enhances human embryonic stem cell to germ-like cell differentiation. Hum Reprod 2010;25:168-178.
49. Yu P, Pan G, Yu J et al. FGF2 sustains NANOG and switches the outcome of BMP4-induced human embryonic stem cell differentiation. Cell Stem Cell 2011;8:326-334.